
Arcturus Therapeutics (ARCT) Stock Forecast & Price Target
Arcturus Therapeutics (ARCT) Analyst Ratings
Bulls say
Arcturus Therapeutics is supported by a differentiated RNA medicines platform whose LUNAR 2.0 delivery technology has shown roughly 38x to 40x higher protein expression in preclinical models, with KOSTAIVE’s full approval validating the company’s self-amplifying mRNA approach and strengthening the vaccine franchise. In OTC deficiency, updated Phase 2 data showed fasting ammonia reduced to or maintained within normal range and glutamine trending lower despite protein intake changes, while management’s plan to transition to ARCT-2601 with FDA alignment and a cleaner preclinical safety package improves the development path and potential convenience profile. The thesis is further reinforced by strategic optionality in cystic fibrosis, including Thermo Fisher support worth up to $40M in clinical manufacturing services and up to $40M in CRO services, which can reduce execution risk and preserve capital while multiple programs advance.
Bears say
Arcturus Therapeutics is facing a negative fundamental outlook because operating expenses and cash burn appear elevated, increasing the likelihood of equity issuances at less attractive valuations and repeated dilution. The company also carries meaningful clinical risk: the ARCT-810 data showed infusion-related reactions, limited interpretability from small and incomplete datasets, no clear biomarker trend, and a study that was terminated after Cohort 1 due to slow enrollment. Longer development timelines, potential formulation changes, regulatory hurdles from the FDA and EMA, and competition from gene-agnostic urea cycle approaches further cloud the path to commercialization and capital efficiency.
This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Arcturus Therapeutics (ARCT) Forecast
Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares